Abstract:Extraocular muscle weakness occurs in most of the myasthenia gravis (MG) patients and it is often the initial complaint. Approximately 10–20% of MG patients with extraocular muscle weakness display only ocular symptoms and rest of the patients subsequently develop generalized muscle weakness. It is not entirely clear why some MG patients develop only ocular symptoms and why extraocular muscle weakness almost always precedes generalized muscle weakness. These facts are often explained by increased susceptibility of extraocular muscles due to their reduced endplate safety factor and lower complement inhibitor expression. Findings of a recently developed animal model of ocular MG suggest that additional factors might be in play. While immunization of HLA transgenic and wild-type (WT) mice with the native acetylcholine receptor (AChR) pentamer carrying conformational epitopes generates severe generalized muscle weakness, immunization of the same mouse strains with recombinant unfolded AChR subunits containing linear epitopes induces ptosis with or without mild generalized muscle weakness. Notably, immunization of mice with deficient T helper cell-mediated antigen presentation with recombinant AChR subunits or whole native AChR pentamer also induces ocular symptoms, AChR-reactive B cells and AChR antibodies. Based on these findings, we hypothesize that ocular symptoms observed in the earlier stages of MG might be triggered by linear and non-conformational AChR epitopes expressed by thymic cells or invading microorganisms. This initial AChR autoimmunity might be managed by T cell-independent and B cell mediated mechanisms yielding low affinity AChR antibodies. These antibodies are putatively capable of inducing muscle weakness only in extraocular muscles which have increased vulnerability due to their inherent biological properties. After this initial attack, as AChR bearing immune complexes form and the immune system gains access to the native AChR expressed by muscle and thymic myoid cells, a more robust anti-AChR autoimmunity develops giving way to high affinity AChR antibodies, thymic germinal center formation and severe generalized muscle weakness. Accurate characterization of chain if events leading to ocular and generalized symptoms in MG might enable development of novel therapeutics that might prevent the transition from mild ocular symptoms to severe generalized weakness in earlier stages of the disease.

Ocular And Generalized Myasthenia Gravis Induced By Human Acetylcholine Receptor ? Subunit Immunization

Ocular Myasthenia Gravis Induced By Human Acetylcholine Receptor Epsilon Subunit Immunization In Hla Dr3 Transgenic Mice

A new mouse model of autoimmune ocular myasthenia gravis.

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Are linear AChR epitopes the real culprit in ocular myasthenia gravis

[Mechanism of Th1/Th2 Cytokines in HLA-DQ8 Transgenic Mice Model of Ocular Experimental Autoimmune Myasthenia Gravis].

Establishment of a Mouse Model of Experimental Autoimmune Myasthenia Gravis

Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci

PATHOGENICITY AND SEQUENCE ANALYSIS OF A MOUSE MONOCLONAL ANTIBODY AGAINST HUMAN ACETYLCHOLINE RECEPTOR IN MYASTHENIA GRAVIS

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis

Artificial Construction of Human Pathogenic Autoantibody in Myasthenia Gravis

Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis

Pathogenesis of Myasthenia Gravis in Transgenic Mouse Induced with Torpedo Acetylcholine Receptor

Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice.

Antigen-specific Immunoadsorption of Anti-acetylcholine Receptor Antibodies from Sera of Patients with Myastenia Gravis

Antibodies Against Low-Density Lipoprotein Receptor-Related Protein 4 Induce Myasthenia Gravis.

Extraocular Muscle Characteristics Related To Myasthenia Gravis Susceptibility

Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the "guided missile" strategy

Agonist antibody to MuSK protects mice from MuSK myasthenia gravis

A novel model of central nervous system involvement in myasthenia gravis

Induce Experimental Autoimmune Myasthenia Gravis on Rats by Passive Transfer Acetylcholine Receptor Monoclonal Antibody